FLT3
HM43239 Granted Fast Track Designation for AML
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
The oral treatment from Aptose Biosciences is in development for relapsed/refractory AML with FLT3 mutation.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |